Trial Profile
Expanded-access for the Use of Setmelanotide in a Single Patient With Partial Lipodystrophy (LD) Associated With Leptin Deficiency and Multiple Autoimmune Diseases
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Jan 2022
Price :
$35
*
At a glance
- Drugs Setmelanotide (Primary)
- Indications Hypertriglyceridaemia; Lipodystrophy; Obesity
- Focus Adverse reactions; Expanded access; Therapeutic Use
- Sponsors Rhythm
- 29 Aug 2017 New trial record